• Robert B. Livingston
  • Stephen K. Carter


Leukeran CB-1348 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Galton, D., Israels, L., Nabarro, J., and Till, M. Clinical trials of p-(di-2-chloroethyl-amino)-phenylbutyric acid (CB 1348) in malignant lymphoma. Brit Med J 2: 1172, 1955.PubMedCrossRefGoogle Scholar
  2. (2).
    Bouroncle, B., Doan, C., Wiseman, B., and Frajola, W. Evaluation of CB 1348 in Hodgkin’s disease and allied disorders. Arch Intern Med 97: 703, 1956.CrossRefGoogle Scholar
  3. (3).
    Bernard, J., Mathe, G., and Weil, M. Therapeutic trial with para-(di-2-chloroethylamino)-phenylbutyric acid in Hodgkin’s disease, chronic lymphoid leukemia and various sarcomas of the lymphoid tissue. (Study on 100 patients). Rev Franc Et Clin Biol 1: 1121, 1956.Google Scholar
  4. (4).
    Altman, S., Haut, A., Cartwright, G., and Wintrobe, M. Early experience with p-(N, N-di-2-chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia. Cancer 9: 512, 1956.PubMedCrossRefGoogle Scholar
  5. (5).
    Shanbrom, E., Knudson, A., and Rapaport, S. Clinical evaluation of chlorambucil. Clin Res Proc 5: 31, 1957.Google Scholar
  6. (6).
    Rottino, A. Therapeutic results in treatment of Hodgkin’s disease with CB 1348 and R-48. Blood 12: 755, 1957.PubMedGoogle Scholar
  7. (7).
    Hansen, P. Clinical experience with CB 1348 in the treatment of chronic lymphatic leukaemia. Acta Radiol 47: 210, 1957.PubMedCrossRefGoogle Scholar
  8. (8).
    Gumport, S., Golomb, F., and Wright, J. Summary of results obtained with CB 1348. Ann N Y Acad Sci 68: 1024, 1958.PubMedCrossRefGoogle Scholar
  9. (9).
    Olson, K. P-(di-2-chloroethyl) aminophenylbutyric acid (CB 1348) in the treatment of cancer. Ann N Y Acad Sci 68: 1017, 1958.PubMedCrossRefGoogle Scholar
  10. (10).
    Ultmann, J., Hyman, G., and Gellhorn, A. Chlorambucil and triethylene thiophosphoramide in the treatment of neoplastic disease. Ann N Y Acad Sci 68: 1007, 1958.PubMedCrossRefGoogle Scholar
  11. (11).
    Doan, C., Wiseman, B., and Bouroncle, B. Clinical evaluation of CB 1348 in leukemias and lymphomas. Ann N Y Acad Sci 68: 979, 1958.PubMedCrossRefGoogle Scholar
  12. (12).
    Israels, L., Galton, D., Till, M., and Wiltshaw, E. Clinical evaluation of CB 1348 in malignant lymphoma and related diseases. Ann N Y Acad Sci 68: 915, 1958.PubMedCrossRefGoogle Scholar
  13. (13).
    Krakoff, I., Karnofsky, D., and Burchenal, J. Remissions induced by chlorambucil in chronic granulocytic leukemia. JAMA 166: 629, 1958.CrossRefGoogle Scholar
  14. (14).
    Rundles, R., Grizzle, J., Bell, W., et al. Comparison of chlorambucil and Myleran in chronic lymphocytic and granulocytic leukemia. Amer J Med 27: 424, 1959.CrossRefGoogle Scholar
  15. (15).
    Miller, D., Diamond, H., and Craver, L. The clinical use of chlorambucil. A critical study. New Eng J Med 261: 525, 1959.PubMedCrossRefGoogle Scholar
  16. (16).
    Masterson, J., Calame, R., and Nelson, J. A clinical study on the use of chlorambucil in the treatment of cancer of the ovary. Amer J Obstet Gyn 79: 1002, 1960.Google Scholar
  17. (17).
    Pinkel, D. Chlorambucil in childhood cancer. Cancer 14: 36, 1961.PubMedCrossRefGoogle Scholar
  18. (18).
    Galton, D., Wiltshaw, E., Szur, L., and Dacie, J. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Brit J Haemat 7: 73, 1961.PubMedCrossRefGoogle Scholar
  19. (19).
    Clatanoff, D., and Meyer, 0. Response to chlorambucil in macroglobulinemia. JAMA 183: 40, 1963.PubMedGoogle Scholar
  20. (20).
    Bigley, R. Treatment of chronic lymphocytic leukemia with triethylene melamine (TEM) and chlorambucil (CB 1348). Cancer Chemother Rep 30: 27, 1963.PubMedGoogle Scholar
  21. (21).
    Kaung, D., Whittington, R., and Patno, M. Treatment of chronic lymphocytic leukemia with chlorambucil (NSC 3088) and cyclophosphamide (NSC 26271). Cancer Chemother Rep 39: 41, 1964.PubMedGoogle Scholar
  22. (22).
    Wiltshaw, E. Chlorambucil in the treatment of primary adenocarcinoma of the ovary. J Obstet Gynaec Brit Cmwlth 72: 586, 1964.CrossRefGoogle Scholar
  23. (23).
    Masterson, J., and Nelson, J. The role of chemotherapy in the treatment of gynecologic malignancy. Amer J Obstet Gynec 93: 1102, 1965.PubMedGoogle Scholar
  24. (24).
    Ezdinli, E., and Stutzman, L. Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA 191: 444, 1965.PubMedCrossRefGoogle Scholar
  25. (25).
    Keettel, W. The treatment of ovarian cancer. Ca 16: 245, 1966.PubMedGoogle Scholar
  26. (26).
    Degos, R., et al. Treatment of Kaposi’s disease with chlorambucil (chloramínophene). Dermatologica 135: 345, 1967.PubMedCrossRefGoogle Scholar
  27. (27).
    McCallister, B., Bayrd, E., Harrison, E., and McGuckin, W. Primary macroglobulinemia. Review with a report on thirty-one cases and notes on the value of continuous chlorambucil therapy. Amer J Med 43: 394, 1967.CrossRefGoogle Scholar
  28. (28).
    Moore, G., Bross, I., Ausman, R., et al. Effects of chlorambucil (NSC 3088) in 374 patients with advanced cancer. Cancer Chemother Rep 52: 661, 1968.PubMedGoogle Scholar
  29. (29).
    Kaung, D., Whittington, R., Spencer, H., and Patno, M. Comparison of chlorambucil and streptonigrin in the treatment of chronic lymphocytic leukemia. Cancer 23: 597, 1969.PubMedCrossRefGoogle Scholar

Copyright information

© IFI/Plenum · New York-Washington-London 1970

Authors and Affiliations

  • Robert B. Livingston
    • 1
  • Stephen K. Carter
    • 1
  1. 1.National Cancer InstituteBethesdaUSA

Personalised recommendations